Sertraline May Improve Core Depressive Symptoms Within 2 Weeks, Analysis Finds
Key Clinical Summary
- A new network analysis of the PANDA trial shows sertraline improves core depressive symptoms, including low mood, self-loathing, and suicidal thoughts, within 2 weeks, earlier than previously reported.
- Emotional and anxiety symptom improvement continues through 12 weeks, while somatic side effects (e.g., fatigue, libido changes) plateau after 6 weeks.
- Findings support sertraline as an effective SSRI for early emotional symptom relief, emphasizing the importance of symptom-level monitoring in optimizing antidepressant therapy.
A recent secondary analysis of the 2019 PANDA randomized controlled trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought. Researchers shared their findings in Nature Mental Health.
The original PANDA trial, which compared sertraline to placebo in patients with depressive symptoms, found that sertraline improved anxiety symptoms and overall mental health at around 6 weeks of treatment but did not meaningfully improve depressive symptoms until about 12 weeks. In this new study, researchers conducted a network analysis to better investigate how specific symptoms responded to treatment.
“Instead of thinking of depression and anxiety as each being a single, uniform condition, network analysis considers that they’re each a constellation of symptoms, that can appear in different combinations for different people,” said corresponding author Giulia G. Piazza, PhD, Department of Clinical, Educational and Health Psychology, University College London, London, UK, in a news release.
Using data from 571 PANDA trial participants, researchers found that all symptoms of anxiety and several core depressive symptoms, including sadness, self-loathing, restlessness, and suicidal thoughts, improved within 2 weeks of sertraline treatment.
READ>>Prenatal Lead Exposure Linked to MDD, Anxiety Symptoms in Later Life
The analysis also found that sertraline contributed to a modest worsening of somatic symptoms, including poor sleep and low libido, within the first 2 weeks of treatments. However, these adverse effects plateaued after 6 weeks, while improvements in emotional symptoms continued from 6 weeks to 12 weeks.
Though these somatic symptoms are frequently reported side effects of selective serotonin reuptake inhibitors (SSRIs), the authors noted that these are also common symptoms of depression, which may complicate the interpretation of treatment effects.
“This intricate pattern of treatment effects is typically masked when measuring depression on a single dimension,” the researchers wrote. “Focusing on individual symptoms of depression and anxiety may shed light on the nature, effectiveness and timing of antidepressant action.”
“Beyond this study, our results highlight the importance of considering symptom-level effects when developing novel drugs and evaluating existing drugs in psychiatry, and how this can help us to understand how these drugs work and how they can help patients,” said co-senior author Jean-Baptiste Pingault, PhD, Department of Clinical, Educational and Health Psychology, University College London, London, UK, in a news release.
While the study offers compelling evidence for the continued use of sertraline as a first-line treatment for anxiety and depressive symptoms, the authors highlight the need for replication in independent samples to further confirm their findings.
